Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2013

Conditions
Respiratory Distress Syndrome
Interventions
DRUG

Curosurf®

Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).

DRUG

Survanta®

Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).

Trial Locations (1)

48109-0245

University of Michigan C & W Mott Children's Hospital, Ann Arbor

Sponsors
All Listed Sponsors
collaborator

Cornerstone Pharmaceuticals

INDUSTRY

lead

University of Michigan

OTHER

NCT01537354 - Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome | Biotech Hunter | Biotech Hunter